Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response

Author： Katz Lior   Gisbert Javier P.   Manoogian Beth   Lin Kirk   Steenholdt Casper   Mantzaris Gerassimos J.   Atreja Ashish   Ron Yulia   Swaminath Arun   Shah Somal   Hart Ailsa   Lakatos Peter Laszlo   Ellul Pierre   Israeli Eran   Svendsen Mads Naundrup   van der Woude C. Janneke   Katsanos Konstantinos H.   Yun Laura   Tsianos Epameinondas V.   Nathan Torben   Abreu Maria   Dotan Iris   Lashner Bret   Brynskov′ Jorn   Terdiman Jonathan P.   Higgins Peter D.R   Chaparro Maria   Ben-Horin Shomron  

Publisher： Blackwell Publishing

ISSN： 1078-0998

Source： Inflammatory Bowel Diseases, Vol.18, Iss.11, 2012-11, pp. : 2026-2033

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Managing Immunogenic Responses to Infliximab: Treatment Implications for Patients with Crohn’s Disease

By Peter D. Han   Russell D. Cohen  

Drugs, Vol. 64, Iss. 16, 2004-01 ,pp. : 1767-1777

Adis International

Access to resources Recommend Favorite

Infliximab promising in paediatric Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. : 19-19

Adis International

Access to resources Recommend Favorite

Infliximab: additional benefits in Crohn's disease

By  

Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Infliximab worth it for Crohn's disease in the UK

By  

Inpharma, Vol. 1, Iss. 1515, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease

By Yu Andrew P.  

PharmacoEconomics, Vol. 27, Iss. 7, 2009-07 ,pp. : 609-621

Adis International

Access to resources Recommend Favorite